Program
bleximenib
Also written as “Bleximenib”, “14C-bleximenib” and “JNJ-75276617”.
Its studies are mostly in Leukemia, Myeloid, Acute · Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by Johnson & Johnson.
Furthest: phase 3, since Feb 25, 20254 company-led studies, 2 open or runningNext primary completion: Dec 29, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 42 open or running | phase 3since Feb 25, 2025 | Mar 22, 2021 | Dec 29, 2028phase 2 · NCT04811560 |
- Named in Johnson & Johnson’s own pipeline as
bleximenib
, phase 3, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First study: phase 2 study in Acute LeukemiaFirst studyNCT04811560 · 420 planned · United States, Australia, Belgium and more
- Aug 29, 2022Phase 1 study in Leukemia, Myeloid, AcuteNCT05521087
- Feb 25, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT06852222 · 600 planned · United States, Australia, Austria and more
- Dec 9, 2025Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07295951 · 6 enrolled · United Kingdom
- Nov 4, 2026Primary completion moved from 2027-02-26 to 2028-12-29Date moved laterphase 2 · +22 months · NCT04811560
Ahead
- Dec 29, 2028Primary completion: phase 2 study in Acute LeukemiaNCT04811560
- Jun 22, 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT06852222
TargetBeta
“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, blexime…”NCIt, read by Claude
“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| revumenibrule | Syndax Pharmaceuticals | phase 3 | 6 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07295951Precursor Cell Lymphoblastic Leukemia-Lymphoma · United Kingdom | 1 | Completed | Jul 21, 2026 | 6 |
| NCT06852222Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Recruiting | Jun 22, 2029 | 600 |
| NCT05521087Leukemia, Myeloid, Acute | 1 | Withdrawn | Sep 11, 2026 | 0 |
| NCT04811560Acute Leukemia · United States, Australia, Belgium and more | 2 | Recruiting | Dec 29, 2028 | 420 |
How it is read
Names in the registry
- “Bleximenib”, 2 entries
- “14C-bleximenib”, 1 entry
- “bleximenib”, 1 entry
- “JNJ-75276617”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 2 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.